The Supreme Court has asked the Centre and the Drug Controller General of India to respond to Micro Labs' appeal against a ban on two fixed-dose combinations for Type II diabetes. This follows a Delhi High Court division bench restoring the government's ban, overturning a previous single-judge order that favored pharmaceutical companies.